The tension between cost containment and the underutilization of effective health services

International Journal of Technology Assessment in Health Care

Volumn 12, Issue 1, 1996, Pages 1-8

  Bloom, Bernard S ^a   Fendrick, A Mark ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIABETIC RETINOPATHY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEPATITIS B; HUMAN; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0029970315     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300009338     Document Type: Review

References (22)

1. Beasley, R. P. Hepatitus B virus. The major etiology of hepatocellular carcinoma. Cancer, 1988, 61; 1942-56.
2. Beasley, R. P., & Hwang, L. Y. Epidemiology of hepatocellular carinoma. In G. N. Vyas, J. L. Dienstag, & J. H. Hoofnagle (eds.), Viral Hepatitis and Liver Disease: Proceedings of the 1984 International Symposium on Viral Replication. New York: Grune and Stratton, 1984.
3. Bloom, B. S., Hillman, A. L., Fendrick, A. M., & Schwartz, J. S. A reappraisal of hepatitis B vaccination strategies using cost-effectiveness analysis. Annals of Internal Medicine, 1993, 118, 298-306.
4. Cochrane, A. L. Effectiveness and efficiency: Random reflections on health services. London: Nuffield Provincial Hospitals Trust, 1972.
5. Dasbach, E. J., Fryback, D. G., Newcomb, P. A., et al. Cost-effectiveness of strategies for detecting diabetic retinopathy. Medical Care, 1991, 29, 20-39.
6. Diabetic Retinopathy Study (DRS) Research Group. Preliminary report on effects of photocoagulation therapy: DRS report number 1. American Journal Ophthalmology, 1976, 81, 383-84.
7. Doorey, A. J., Michelson, M. D., Topol, E. J. Thrombolytic therapy in acute myocardial infarction: Keeping the unfulfilled promises. Journal of the American Medical Association, 1992, 268, 3108-14.
8. Fendrick, A. M., Javitt, J. C., & Chiang, Y. P. Cost-effectiveness of the screening and treatment of diabetic retinopathy. International Journal of Technology Assessment in Health Care, 1992, 8, 684-707.
9. Fendrick, A. M., Ridker, P. M., & Bloom, B. S. Improved health benefits of increased and expanded utilization of thrombolytic therapy. Archives Internal Medicine 1994, 154, 1605-09.
10. Ferris, F. L. How effective are treatments for diabetic retinopathy? Journal of the American Medical Association, 1993, 269, 1290-91.
11. Grimes, D. A. Technology follies: The uncritical acceptance of medical innovation. Journal of the American Medical Association 1993, 269, 3030-33.
12. Javitt, J. C., Canner, J. K., & Sommer. A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetes. Ophthalmology, 1989, 96, 255-64.
13. Jefferson, T., & Demicheli, V. Is vaccination against hepatitis B efficient? A review of world literature. Health Economics, 1994, 3, 25-37.
14. Krahn, M., & Detsky, A. S. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Medical Decision Making, 1993, 13, 4-20.
15. Lairson, D. Cost-effectiveness of alternative methods for diabetic retinopathy screening. Diabetes Care, 1992, 15, 1369-77.
16. LATE Study Group. Late assessment of thrombolytic efficacy (LATE): Study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet, 1993, 342, 759-66.
17. MMWR Morbid and Mortal Weekly Report, 1993, 41, 1-74.
18. Moertel, C. G., Fleming, T. R., MacDonald, J. S., & Haller, D. G. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. Journal of the American Medical Association, 1993, 270, 943-47.
19. Protection Against Viral Hepatitis: Recommendations of the Immunization Practices Advisory Committee. MMWR Morbid Mortal Weekly Report, 1990, 39, 1-26.
20. Rettig, R. A. Medical innovation duels cost containment. Health Affairs, 1994, 13, 7-27.
21. Schieber, G. J., Poullier, J.-P., & Greenwald, L. M. Health spending, delivery, and outcomes in OECD countries. Health Affairs, 1993, 12, 120-30.
22. Sussman, E. J., Tsiaras, W. G., & Soper, K. A. Diagnosis of diabetic eye disease. Journal of the American Medical Association, 1982, 247, 3231-34.